Drug profile · INN
natalizumab-sztn
TYRUKO
natalizumab-sztn (TYRUKO) is a integrin alpha-4/beta-1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — natalizumab-sztn
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
natalizumab-sztn (TYRUKO) is a integrin alpha-4/beta-1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Integrin alpha-4/beta-1 inhibitor
Primary target: Integrin alpha-4/beta-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is natalizumab-sztn?
natalizumab-sztn (TYRUKO) is a integrin alpha-4/beta-1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for natalizumab-sztn?
TYRUKO is a marketed brand name for natalizumab-sztn. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of natalizumab-sztn?
natalizumab-sztn has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.